BI 695501
BI 695501 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
Pharmacokinetics and Safety in Healthy Volunteers
Clinical Trials (6)
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
Pharmacokinetics and Safety in Healthy Volunteers
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6